Clinical Trial Info

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK)

Authored by

This is a phase 2 study in which 40 subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Gen1) or VIR-7831 (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics.